SEC Form 4 · accession 0001209191-16-104942

Sarepta Therapeutics, Inc. · SRPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President, CFO

Period of report

Feb 29, 2016

Accepted (ET)

Mar 2, 2016 · 9:27 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000873303

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 29, 2016	A	3,115	$0.00	A	8,115	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F2	$13.71	Feb 29, 2016	A	3,534	A	—	Feb 28, 2026	Common Stock	3,534	3,534	D
Non-Qualified Stock Option (right to buy)^F2	$13.71	Feb 29, 2016	A	33,966	A	—	Feb 28, 2026	Common Stock	33,966	33,966	D
Incentive Stock Option (right to buy)^F3	$13.71	Feb 29, 2016	A	521	A	—	Feb 28, 2026	Common Stock	521	521	D
Non-Qualified Stock Option (right to buy)^F3	$13.71	Feb 29, 2016	A	36,979	A	—	Feb 28, 2026	Common Stock	36,979	36,979	D

F1100% of the Restricted Stock Award granted on February 29, 2016 vests six months from the date of grant. This award is being provided in lieu of a portion of the executive's cash bonus and is subject to continued service with the Issuer.
F225% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.
F3Half of the options begin vesting in the event the FDA provides marketing approval for eteplirsen as of the applicable PDUFA date and the other half of the options begin vesting in the event Sarepta files a Marketing Authorization Application with the EMEA prior to December 31, 2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vests immediately upon achievement of the performance condition (25% of the total Performance-Based Options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total Performance-Based Options granted) vests over four years with 25% of these remaining options vesting on the first year anniversary of the grant date and 1/48th of these remaining options vesting monthly thereafter.